Martin-Immanuel Bittner to present at the 6th Ageing Research, Drug Discovery, and AI Forum in Basel
Credit: Insilico Medicine
Wednesday, August 7, 2019 – Today Insilico Medicine, a biotechnology company developing the end-to-end drug discovery pipeline utilizing next generation artificial intelligence, and the Scheibye-Knudsen Lab, University of Copenhagen, announce the presentation of Martin-Immanuel Bittner, MD DPhil, Co-Founder and CEO of Arctoris, at the 6th Ageing Research, Drug Discovery, and AI Forum during the Basel Life Congress, September 10-12, 2019 in Basel, Switzerland.
Drug discovery starts in the lab, and billions are spent on lab-based research every year. However, today this research is considered slow, expensive, and unreliable. More than 80% of research findings are deemed irreproducible, whilst researchers in academia and biotech companies spend 7 to 8 hours every day with manual work, and only a fraction of that time with genuine scientific work. A survey of the biotech and pharma landscape as well as emerging technology companies within the life sciences industry reveals now major shifts in the ecosystem.
Arctoris is a technology company that designed and built a fully automated research facility based in Oxford (UK), where robotics perform a range of the most frequent cell-based and biochemical drug discovery assays for researchers worldwide.
“Drug discovery researchers worldwide face enormous challenges posed by the limited availability of data standards and widespread lack of reproducibility. The rise of robotics can mitigate these challenges and enable researchers to produce data of unprecedented quality and accuracy, accelerating the drug discovery process,” said Martin-Immanuel Bittner, MD DPhil, Co-Founder and CEO of Arctoris.
Automated experimentation makes the drug discovery process faster, cheaper, and more reliable. Precise automation, encompassing capture of data and its storage in a secure and structured form provide a powerful combination that is in line with the recent trend towards data-driven drug discovery.
“We are very excited to welcome Dr. Martin Immanuel Bittner in Basel this year. As a co-founder and CEO of Arctoris, he is driving the field of robotic cloud lab to the next level. A pipeline that may strongly change our daily scientific life in the near future. The move towards increased standardization and automation will be important to accelerate data acquisition as well as drug discovery,” said Dr. Daniela Bakula, University of Copenhagen.
“Over the last 5 years, the “Ageing & Drug Discovery” and “AI for Healthcare” forums have been leading events at Basel Life, attracting hundreds of delegates from over 50 countries. This year, we are combining the 2 platforms into a 3 day-event titled “the 6th Ageing, AI and Drug Discovery Forum” to explore the convergence of these 2 cutting edge disciplines. Under the program leadership of Professor Morten Scheibye-Knudsen and Dr. Alex Zhavoronkov, with distinguished scientists and industry experts in the field, we look forward to exploring breakthroughs for this great healthcare need for the planet,” said Dr. Bhupinder Bhullar, Chair, Innovation Forum program committee, Basel Life 2019.
“The 6th annual Ageing Research, Drug Discovery, and AI Forum at Basel Life will have a fresh program featuring some of the most prominent scientists and industry players in ageing and longevity research covering the theory, applications and convergence of these three exciting areas,” said Alex Zhavoronkov, Ph.D., Founder, and CEO of Insilico Medicine, Inc.
The 6th Ageing Research, Drug Discovery, and AI Forum Basel will bring together leaders in the ageing, longevity, and drug discovery field, to describe the latest progress in the molecular, cellular and organismal basis of ageing and the search for interventions. Furthermore, the forum will include opinion leaders in AI to discuss the latest advances of this technology in the biopharmaceutical sector and how this can be applied to interventions. This event intends to bridge academic and commercial research and foster collaborations that will result in practical solutions to one of humanity’s most challenging problems: ageing. The Forum will be held in Basel, Switzerland, September 10-12, 2019.
For further information, images or interviews, please contact:
Ola Popova [email protected]
About Martin-Immanuel Bittner, MD DPhil
Martin-Immanuel Bittner is a Co-Founder and CEO of Arctoris, the world’s first cloud lab dedicated to cancer drug discovery. Martin graduated as a medical doctor from the University of Freiburg in Germany, followed by his DPhil in Oncology as a Rhodes scholar at the University of Oxford. He has an extensive research experience covering both clinical trials and preclinical drug discovery and is an active member of several leading cancer research organisations, including AACR, EACR, ESTRO and EORTC. In recognition of his research achievements, he was elected a member of the Young Academy of the German National Academy of Sciences in 2018.
Arctoris is an Oxford-based cloud lab for academic centres and biotech companies working in drug discovery, particularly in cancer research. Arctoris offers experiments-as-a-service, enabling scientists to configure their experiments remotely and have them executed on the Arctoris robotic platform. Thanks to total automation, experiments are fast, consistent and precise and the resulting data is rich and reliable, accelerating the research process. Researchers can focus on the science instead of spending hours every day with lab work, helping them to save time and money. Arctoris performs a wide range of cell-based and biochemical experiments, with more capabilities being added all the time. Arctoris already serves academic centres and biotech companies in Europe and the US, currently expanding to Asia-Pacific.
Official website: https:/
About Insilico Medicine, Inc
Insilico Medicine is an artificial intelligence company headquartered in Hong Kong, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and ageing research.
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Ageing Research and Drug Development Award accompanied with the industry brief. Brief company video: https:/
Official website: http://insilico.
About the Scheibye-Knudsen Laboratory
The growing proportion of the elderly population represents an increasing socioeconomic challenge, not least because of age-associated diseases. It is therefore increasingly pertinent to find interventions for age-associated diseases such as Alzheimer’s, Parkinson’s and cardiovascular diseases. Although the cause of ageing is currently unknown accumulation of damage to our genome, the DNA, may be a contributing factor.
In the Scheibye-Knudsen lab we try to understand the cellular and organismal consequences of DNA damage with the aim of developing interventions. We have discovered that DNA damage leads to changes in certain metabolites and that replenishment of these molecules may alter the rate of ageing in model organisms. These findings suggest that normal ageing and age-associated diseases may be malleable to similar interventions. The hope is to develop interventions that will allow everyone to live healthier, happier and more productive lives.
Laboratory website: http://scheibye-knudsen.
About the University of Copenhagen
With over 40,000 students and more than 9,000 employees, the University of Copenhagen is the largest institution of research and education in Denmark and among the highest ranked universities in Europe. The purpose of the University – to quote the University Statute – is to ‘conduct research and provide further education to the highest academic level’. Approximately one hundred different institutes, departments, laboratories, centres, museums, etc., form the nucleus of the University.
University Website: http://introduction.
About Basel Life 2019
Ageing Research for Drug Discovery Forum description
In this symposium, leaders in the ageing, longevity, and drug discovery field will describe the latest progress in the molecular, cellular and organismal basis of ageing and the search for interventions. Furthermore, the forum will include opinion leaders in AI to discuss the latest advances of this technology in the biopharmaceutical sector and how this can be applied to interventions. This event intends to bridge academic and commercial research and foster collaborations that will result in practical solutions to one of humanity’s most challenging problems: ageing. A panel of thought-leaders will give us their cutting edge reports on the latest progress in our quest to extend the healthy lifespan of everyone on the planet.
Conference Official Website: https:/